Publications by authors named "F Mercurio"
In recent decades, peptides have attracted significant attention not only from Academia but also from big Pharma as novel potential therapeutic compounds [...
View Article and Find Full Text PDFArticle Synopsis
- Peptide building blocks can create supramolecular nanostructures that effectively deliver various drugs while their design impacts the ability of these structures to interact with specific drugs.
- The study focuses on hybrid cationic peptide hydrogels, combining a low-molecular-weight hydrogelator with different cationic amphiphilic peptides to analyze their structural properties.
- Findings indicate that the hydrogel's structure is primarily determined by the hydrogelator, while the peptides' alkyl chain lengths significantly influence the material's morphology, stiffness, and drug encapsulation capabilities.
Article Synopsis
- The Sam domain of Ship2 interacts with EphA2, contributing to cancer development, making this connection a potential therapeutic target.
- Researchers used FoldX software to design peptides that could disrupt the EphA2-Sam/Ship2-Sam complex, focusing on the Mid Loop interface of Ship2-Sam.
- Promising new peptides were tested to assess their effectiveness in disrupting the interaction, their cytotoxic effects on cancer versus healthy cells, and their role in EphA2 degradation, paving the way for future strategies in targeting similar protein interactions.
The Sam (sterile alpha motif) domain from the lipid phosphatase Ship2 binds the Sam domain from the EphA2 receptor to negatively regulate receptor endocytosis and degradation. This interaction is primarily linked to pro-oncogenic effects. We report on the design and evaluation of EphA2-Sam/Ship2-Sam peptide inhibitors provided with positive charges and different aromatic characters.
View Article and Find Full Text PDFImportance: The recent change in terminology from nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated fatty liver disease (MAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD) highlights the link between hepatic steatosis and metabolic dysfunction, taking out the stigmata of alcohol.
Objective: We compared the effects of NAFLD and MAFLD definitions on the risk of overall and cardiovascular (CV) mortality, liver-related events (LRE), nonfatal CV events (CVE), chronic kidney disease (CKD), and extra-hepatic cancers (EHC).
Data Sources And Study Selection: We systematically searched four large electronic databases for cohort studies (published through August 2023) that simultaneously used NAFLD and MAFLD definitions for examining the risk of mortality and adverse CV, renal, or oncological outcomes associated with both definitions.